Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
about
Current treatment options for local residual nasopharyngeal carcinomaRole of chemotherapy in nasopharyngeal carcinomaMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsPhase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinomaFactors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit?Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.Predictors for replanning in loco-regionally advanced nasopharyngeal carcinoma patients undergoing intensity-modulated radiation therapy: a prospective observational study.Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study.Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivoIn vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Nasopharyngeal carcinoma: alternative treatment options after disease progression.Metastasectomy for metachronous pulmonary and hepatic metastases from nasopharyngeal carcinoma: Report of 6 cases and review of the literature.Investigational drugs for nasopharyngeal carcinoma.Capecitabine for treating head and neck cancer.Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: A meta-analysisAssociation of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line.Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinomaGemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma.Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review.Head and neck cancer in Hong Kong.Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update.Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells.
P2860
Q26852207-E282D432-88CB-4F81-9B3D-5EACFC9ADA4FQ27022454-9F8C11AB-CC7F-4523-A932-152590ED2E7CQ30846827-E5269056-667D-4A2C-ACA5-326934D707CDQ33377668-70A9E3E5-BC89-48EB-A1D8-CBD0D60B6AB9Q33398185-C85E0A95-2F25-43BF-B267-B3023B9D39EFQ33404307-631BCEFC-9528-455B-9C6F-52DEDD411889Q33428012-BD40530F-C019-4E51-BD47-B1F0EA281436Q33428455-16A24B15-9C9C-497E-8BF8-AF37E28D35E7Q34001937-5767D7FD-1715-4442-8275-ECC07F5709ABQ34242449-AFF0D23A-18EC-41C5-AA59-CB786308E066Q35044383-CFEA9CF3-E184-46EA-BFA9-4B681143B801Q35670921-D202FDFC-B850-44FC-B52F-F5063337047CQ36158012-3F5336C1-4E81-4686-9EE8-94F5BB8E756DQ36407458-52AD1C6C-9A36-4253-BF22-92826C8B42A2Q36710062-2E2F4C38-D7D7-4118-BB27-CC5691D55479Q36766842-247C3D9F-CA94-4F6C-837A-EF6268F40681Q36915011-11BBF6B6-9845-4A51-9308-256D538D7949Q37171008-56B5C4CD-2744-4FF5-9216-88BB52C13648Q37183598-D68D04C0-7BAE-4F33-A9A2-81BD800B3308Q37248002-EF483666-0CA1-4759-A049-75428DAA4AFAQ37690437-B025C36A-1853-4BAC-B6A9-3384DEF07DFDQ37705415-C47F6016-44F6-45EF-B4B4-A0B38958FB1CQ38452359-0AFB0695-AFD4-4851-8FA2-B965C2404D12Q38690528-3B244E7D-E3DF-493B-841C-54F1043F9442Q38825147-3F81A4D2-97B2-4626-A5A4-1FAF7B9A66EBQ38943596-74A6E70D-DD00-4F00-B04C-FCF8CDD0960EQ39680524-1CEAA22F-4409-45E4-A8A2-43EB2B44698EQ40078689-DC2BA3E8-D6E0-4BD0-BEA5-5C6D5D3E7140Q40323714-2CC8B8FD-1AF2-46D9-9B00-5D6BDFC8EC49Q41538061-F3657D38-C1D3-4973-961D-28FDFC2F576BQ41592916-3D92E9B6-C005-4386-8735-2B3456ECCC19Q41684880-940D419B-A364-478D-B0DE-CBA99D8C4D57Q43771934-E91AC827-A15A-412F-8C3F-EEBCA523220FQ45361755-865FD318-3902-4689-804C-919D5EDABD1CQ47729318-C4B64536-F26B-42C4-B92B-FEDD25790E7CQ49960053-4E81E90D-3D7E-4BF1-9989-7F23DA44AE37Q50137405-D1D195FF-39CB-413E-B47A-FA01FDE4EF38Q54116634-A832A6BE-37B4-41D3-A321-586437DC9A84
P2860
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Combination gemcitabine and ci ...... a: report of a phase II study.
@ast
Combination gemcitabine and ci ...... a: report of a phase II study.
@en
type
label
Combination gemcitabine and ci ...... a: report of a phase II study.
@ast
Combination gemcitabine and ci ...... a: report of a phase II study.
@en
prefLabel
Combination gemcitabine and ci ...... a: report of a phase II study.
@ast
Combination gemcitabine and ci ...... a: report of a phase II study.
@en
P2093
P2860
P356
P1433
P1476
Combination gemcitabine and ci ...... ma: report of a phase II study
@en
P2093
F Y Cheung
R K C Ngan
P2860
P304
P356
10.1093/ANNONC/MDF200
P50
P577
2002-08-01T00:00:00Z